The role of serotonin in hot flushes

Maturitas

Volumn 36, Issue 3, 2000, Pages 155-164

  Berendsen, Hemmie H G ^a  

^a NV ORGANON   (Netherlands)

Author keywords

5 HT2A receptors; Estrogen withdrawal; Hot flush; Menopause; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; AUTORECEPTOR; CATECHOLAMINE DERIVATIVE; CLONIDINE; ESTROGEN; MEGESTROL; METHYLDOPA; MIANSERIN; PROGESTERONE RECEPTOR; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; VERALIPRIDE;

ARTICLE; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; MENOPAUSE; SEROTONINERGIC SYSTEM; SKIN TEMPERATURE; SLEEP; SWEATING; VASODILATATION;

ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMAN; MENOPAUSE; PROGESTERONE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0034739634     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00151-1     Document Type: Article

References (95)

1. Treatment of menopausal hot flashes with transdermal administration of clonidine
2. Well-being, symptoms and the menopausal transition
3. Objective measurement of hot flushes associated with the premenstrual syndrome
4. Menopausal-like hot flashes reported in women of reproductive age
5. Core body temperature and circadian rhythm of hot flashes in menopausal women
6. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes
7. Postmenopausal hot flushes and their management
8. Temperature guardian neurons in the preoptic area of the hypothalamus
9. Hot flashes-physiology, hormonal therapy, and alternative therapies
10. Megestrol acetate for prevention of hot flashes
11. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes
12. Steroid regulation of estrogen and progestin receptor messenger ribonucleic acid in monkey hypothalamus and pituitary
13. Pathophysiology of postmenopausal hot flushes
14. Management of menopause when estrogen cannot be used
15. Hormone replacement therapy and endometrial cancer risk: a meta-analysis
16. The biology of menopause
17. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause
18. Endocrine changes and symptomatology after oophorectomy in premenopausal women
19. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density
20. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism
21. The physiology and measurement of hot flushes
22. Basic psychopharmacology of antidepressants, Part 2: estrogens as an adjunct to antidepressant treatment
23. Reduction of menopausal hot flushes by methyldopa
24. Effects of intravenous clonidine on menopausal flushing and luteinizing hormone secretion
25. Treatment of menopausal hot flashes with transdermal administration of clonidine
26. 2-Adrenergic mechanism in menopausal hot flushes
27. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin
28. Failure of response of menopausal vasomotor symptoms to clonidine
29. A comparison of oestrogen-progestogen with clonidine in the climacteric syndrome
30. A double blind trial with clonidine and a placebo to treat hot flushes
31. Transdermal clonidine for ameliorating post-orchiectomy hot flashes
32. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes
33. Effect of clonidine on hot flashes in menopausal women
34. Troubles de la fonction cerebrale au climatere et leur prophylaxie
35. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia?
36. Estrogen and the treatment of Alzheimer's disease
37. Discinesia respiratoria inducida por veralipride
38. Troubles extrapyramidaux induits par le veralipride (Agreal). A propos de cinq observations
39. Sindrome parkinsoniana indotte da veralipride
40. Panic-like symptoms after veralipride withdrawal
41. Management of menopause in women with breast cancer
42. Postmenopausal hormone therapy and breast cancer
43. Menopause: when hormone replacement therapy is not an option
44. Proposal for the classification and nomenclature of functional receptors for 5-hydroxytryptamine
45. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
46. 5-Hydroxytryptamine: Considerations about discovery, receptor classification and relevance to medical research
47. Interactions between 5-hydroxytryptamine receptor subtypes: Is a disturbed receptor balance contributing to the symptomatology of depression in humans?
48. Vascular receptors for 5-hydroxytryptamine, distribution, function and classification
49. Effects of steroid hormones on the serotonergic system
50. The influence of sex hormones on antidepressant induced alterations in neurotransmitter receptor binding
51. Modulation by estradiol of serotonin receptors in brain
52. Serotonergic and noradrenergic receptors in the rat brain: modulation by chronic exposure to ovarian hormones
53. Blood serotonin levels in postmenopausal women: effects of age and serum estradiol levels
54. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women
55. Estrogen augments serotonergic activity in postmenopausal women
56. Urinary 5-hydroxyindole acetic acid excretion after estradiol treatment of menopausal women
57. Oestrogen and mental state
58. Increased serotonin 5-HT2 receptor binding on blood platelets of suicidal men
59. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims
60. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects
61. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat
62. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors
63. Oestrogen modulates progestin receptor concentrations in some rat brain regions but not in others
64. Colocalization of progestin receptors with serotonin in raphe neurons of macaque
65. Regulation of progestin receptors in the raphe neurons of steroid-treated monkeys
66. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques
67. Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques
68. The perimenopausal hot flash: epidemiology, physiology, and treatment
69. A model to measure anticipatory anxiety in mice?
70. Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtype
71. A new peptide, 5HT-moduline, isolated and purified from mammalian brain specifically interacts with 5HT1B/1D receptors
72. 5-Hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine 1B/1D receptors
73. Acute stress induces a differential increase of 5-HT-moduline levels in various rat brain areas
74. The effect of ovariectomy and oestrogen replacement on small artery biomechanics in the rat
75. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study
76. Cardiovascular responses during the menopausal hot flush
77. Interaction between enantiomers of mianserin and Org 3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells
78. Mirtazapine in menopausal depression
79. Clinical experience with mianserin hydrochloride for treatment of climacteric complaints
80. Functional correlates of serotonin 5-HT1 recognition sites
81. Serotonin function in anxiety II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects
82. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers
83. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study
84. Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine
85. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice
86. An open trial of sertraline for menopausal hot flushes: potential involvement of serotonin in vasomotor instability
87. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer
88. Pilot evaluatiom of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
89. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer
90. Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure
91. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period